Import Alerts: How the FDA Blocks Drugs from Non-Compliant Manufacturers in 2026
Mar 25 2026
Paragraph IV Certifications: How Generics Challenge Patents to Lower Drug Prices
Learn how Paragraph IV certifications allow generic drugs to challenge brand-name patents under the Hatch-Waxman Act. Explore the legal process, 180-day exclusivity, and cost implications.
